Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, has announced the issuance of equity inducement grants to seven new non-officer employees. A total of 55,300 share options have been allocated, each with an exercise price of $38.60 per common share. These options are set to vest over four years, with 25% vesting after the first year and the remainder vesting monthly over the following three years. Each option carries a 10-year term, offering new employees a long-term stake in the company's success.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520648-en) on August 29, 2025, and is solely responsible for the information contained therein.